Table 4

Response rate in relapsed/refractory MCL patients receiving idelalisib

CategoryAll patients (N = 40)Receiving <150 mg bid* (n = 24)Receiving ≥150 mg qd (n = 16)
ORR 16 (40) 5 (21) 11 (69) 
CR 2 (5) 2 (12.5) 
PR 14 (35) 5 (21) 9 (56.3) 
SD 19 (47.5) 15 (62.5) 4 (25) 
PD 4 (10) 4 (16.7) 
NE 1 (2.5) 1/16 (6.3) 
CategoryAll patients (N = 40)Receiving <150 mg bid* (n = 24)Receiving ≥150 mg qd (n = 16)
ORR 16 (40) 5 (21) 11 (69) 
CR 2 (5) 2 (12.5) 
PR 14 (35) 5 (21) 9 (56.3) 
SD 19 (47.5) 15 (62.5) 4 (25) 
PD 4 (10) 4 (16.7) 
NE 1 (2.5) 1/16 (6.3) 

Data are presented as number (%) of patients.

bid, twice daily; CR, complete response; NE, not evaluable; PR, partial response; qd, daily.

*

Dose cohorts include 150 mg daily, 150 mg twice daily × 21 days, 50 mg twice daily, and 100 mg twice daily.

Dose cohorts include 300 mg daily, 150 mg twice daily, 200 mg twice daily, and 350 mg twice daily.